Imperial College London

Professor Anthony Gordon

Faculty of MedicineDepartment of Surgery & Cancer

Chair in Anaesthesia and Critical Care







ICUQueen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus






BibTex format

author = {Gordon, AC and Santhakumaran, S and Al-Beidh, F and Orme, RML and Perkins, GD and Singer, M and McAuley, DF and Mason, AJ and Ward, JK and ODea, KP and Felton, T and Cross, M and Best-Lane, J and Lexow, J and Campbell, A and Ashby, D},
doi = {10.3310/eme05060},
journal = {Efficacy and Mechanism Evaluation},
pages = {1--94},
title = {Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT},
url = {},
volume = {5},
year = {2019}

RIS format (EndNote, RefMan)

AB - <jats:sec id="abs1-1"> <jats:title>Background</jats:title> <jats:p>In septic shock, cardiovascular resuscitation using catecholamine vasopressors and inotropes is standard therapy, but catecholamines have important side effects. Levosimendan (Simdax<jats:sup>®</jats:sup>; Orion Pharma, Newbury, UK) is a calcium-sensitising drug with inotropic and other properties that may have a role in sepsis.</jats:p> </jats:sec> <jats:sec id="abs1-2"> <jats:title>Objectives</jats:title> <jats:p>To determine, in adult septic shock, whether or not levosimendan reduces the incidence and severity of acute organ dysfunction, the effect of levosimendan on individual organ function and the safety profile of levosimendan.</jats:p> </jats:sec> <jats:sec id="abs1-3"> <jats:title>Design</jats:title> <jats:p>Multicentre, randomised, double-blind, parallel-group, placebo-controlled study.</jats:p> </jats:sec> <jats:sec id="abs1-4"> <jats:title>Setting</jats:title> <jats:p>UK intensive care units.</jats:p> </jats:sec> <jats:sec id="abs1-5"> <jats:title>Participants</jats:title> <jats:p>Adult patients with sepsis and cardiovascular failure requiring vasopressors to maintain blood pressure despite adequate fluid resuscitation.</jats:p> </jats:sec> <jats:sec id="abs1-6"> <jats:title>Intervention</jats:title> <jats:p>Levosimendan, at a dosage of 0.05–0.2 µg/kg/minute
AU - Gordon,AC
AU - Santhakumaran,S
AU - Al-Beidh,F
AU - Orme,RML
AU - Perkins,GD
AU - Singer,M
AU - McAuley,DF
AU - Mason,AJ
AU - Ward,JK
AU - ODea,KP
AU - Felton,T
AU - Cross,M
AU - Best-Lane,J
AU - Lexow,J
AU - Campbell,A
AU - Ashby,D
DO - 10.3310/eme05060
EP - 94
PY - 2019///
SN - 2050-4365
SP - 1
TI - Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT
T2 - Efficacy and Mechanism Evaluation
UR -
VL - 5
ER -